In order to develop an oestrogen
treatment that utilises the favourable effects of the oestrogen
but not its side-effects, researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have analysed which parts of the oestrogen
receptor is most important in enabling oestrogen
to act on bone tissue and other tissues.
Previously, inactivation of the oestrogen
receptor has been shown to be mainly via DNA methylation or histone acetylation and in this type of oestrogen
receptor-negative environment the only way of re-expressing the oestrogen
receptor has been via DNA methylation inhibitors or histone deacetylation compounds.